Atypical Mycobacteriosis Treatment Market Report 2026

The atypical mycobacteriosis treatment market size has grown strongly in recent years. It will grow from $2.4 billion in 2025 to $2.54 billion in 2026 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to improved clinical recognition of ntm infections, increased availability of macrolide-based therapies, expansion of specialized infectious disease care, rising hospital-based treatment adoption, improved diagnostic differentiation from tuberculosis.

The atypical mycobacteriosis treatment market size is expected to see strong growth in the next few years. It will grow to $3.17 billion in 2030 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to growing prevalence of immunocompromised populations, increasing research into novel antimycobacterial agents, rising adoption of personalized treatment approaches, expansion of outpatient and home-based care, improved clinical guidelines for ntm management. Major trends in the forecast period include increasing use of combination antibiotic regimens, rising focus on drug-resistant ntm management, growing adoption of long-duration treatment protocols, expansion of targeted surgical interventions, enhanced emphasis on supportive and adjunctive care.

The increasing demand for personalized therapies is anticipated to drive the growth of the atypical mycobacteriosis treatment market in the coming years. Personalized therapies are medical treatments designed to align with an individual's specific genetic, biological, and environmental factors to enhance effectiveness. This rising demand is largely fueled by advancements in genomics and biotechnology, which facilitate the development of treatments tailored to individual genetic profiles, thereby improving outcomes and reducing side effects. Atypical mycobacteriosis treatment plays a key role in personalized therapies, as it enables the creation of customized treatment approaches based on the unique genetic and clinical characteristics of each patient, resulting in more accurate and effective care. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases, a notable increase from six approvals in 2022. Consequently, the rising demand for personalized therapies is propelling the growth of the atypical mycobacteriosis treatment market.

The increasing prevalence of chronic obstructive pulmonary disease is anticipated to drive the growth of the atypical mycobacteriosis treatment market in the coming years. Chronic obstructive pulmonary disease (COPD) encompasses a group of progressive lung disorders, including emphysema and chronic bronchitis, which cause airflow obstruction and breathing difficulties. The rising prevalence of COPD is largely attributed to tobacco smoke, as prolonged exposure to harmful chemicals in tobacco damages the lungs and airways, resulting in chronic inflammation and airflow limitation. Atypical mycobacteriosis treatment aids in managing COPD by reducing the bacterial load and inflammation caused by nontuberculous mycobacteria, which can worsen respiratory symptoms and accelerate disease progression. For example, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, COPD accounted for 3.6% of the country’s total disease burden and represented 50% of the overall burden from respiratory conditions in 2023, up from 2.5% of the population living with COPD in 2022, reflecting a 44% year-over-year increase in disease burden share. Consequently, the rising prevalence of COPD is fueling the growth of the atypical mycobacteriosis treatment market.

Major companies are active in the atypical mycobacteriosis treatment market, concentrating on developing innovative solutions such as oral oxaborole antibiotics to address the growing need for safer, more effective, and long-term therapies for non-tuberculous mycobacterial (NTM) infections. Oxaboroles represent a novel class of small-molecule drugs that inhibit bacterial protein synthesis through a boron-based mechanism, providing a unique mode of action compared to conventional antimycobacterial treatments, while minimizing toxicity, resistance, and drug-drug interactions. For example, in January 2025, MicuRx Pharmaceuticals, a China-based biopharmaceutical company, introduced MRX-5, an orally bioavailable oxaborole antibiotic developed for NTM infections. The drug showed dose-dependent reductions in lung bacterial load in preclinical models of Mycobacterium abscessus, exhibited favorable pharmacokinetics, minimal drug-drug interactions, high oral bioavailability, and is intended for chronic use in patients requiring long-term therapy.

Major companies operating in the atypical mycobacteriosis treatment market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Zydus Pharmaceuticals, Lupin Limited, Gland Pharma Limited, Saphnix Lifesciences Pvt. Ltd., Gentec Pharmaceutical Group, Octavius Pharma Pvt. Ltd.

North America was the largest region in the atypical mycobacteriosis treatment market in 2025. The regions covered in the atypical mycobacteriosis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the atypical mycobacteriosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the atypical mycobacteriosis treatment market by increasing costs of imported active pharmaceutical ingredients, injectable antibiotics, sterile packaging materials, and specialized medical devices used in prolonged treatment regimens. Hospitals and specialty clinics in North America and Europe are most affected due to reliance on global pharmaceutical supply chains, while Asia-Pacific faces higher production and sourcing costs. These tariffs are contributing to higher therapy costs and procurement delays. However, they are also encouraging local drug manufacturing, regional sourcing of APIs, and increased investment in domestic pharmaceutical production capabilities.

The atypical mycobacteriosis treatment market research report is one of a series of new reports that provides atypical mycobacteriosis treatment market statistics, including atypical mycobacteriosis treatment industry global market size, regional shares, competitors with a atypical mycobacteriosis treatment market share, detailed atypical mycobacteriosis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the atypical mycobacteriosis treatment industry. This atypical mycobacteriosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Atypical mycobacteriosis treatment involves the medical management of infections caused by nontuberculous mycobacteria (NTM), a group of mycobacterial species that do not cause tuberculosis. These infections can impact different parts of the body, including the lungs, skin, and lymph nodes, and are frequently more resistant to standard tuberculosis therapies. Treatment usually consists of a combination of antibiotics, such as macrolides, rifamycins, and ethambutol, often administered over an extended period.

The primary treatment approaches for atypical mycobacteriosis include antibiotic therapy, surgical interventions, combination therapy, and supportive care. Antibiotic therapy entails the extended use of specific antibiotics such as macrolides, aminoglycosides, and fluoroquinolones to eradicate or control the growth of atypical mycobacteria and reduce the risk of recurrence. This method is applied to various types of infections, including atypical mycobacterial lung infections, disseminated infections, and skin and soft tissue infections, and involves different routes of drug administration, such as oral, intravenous, and topical methods. Treatment is provided to diverse patient groups, including immunocompromised patients, non-immunocompromised patients, and pediatric patients, and is utilized across multiple care settings, such as hospitals, clinics, and home healthcare environments.

The atypical mycobacteriosis treatment market consists of revenues earned by entities by providing services such as diagnosis and screening, consultation and care management, surgical intervention, patient education and support services, telemedicine services, inpatient and outpatient care, personalized treatment plans, pharmacovigilance and drug monitoring, nutritional support and counseling, and laboratory and diagnostic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The atypical mycobacteriosis treatment market also includes sales of clarithromycin, azithromycin, rifampin, ethambutol, amikacin, streptomycin, rifabutin, pyrazinamide, interferons, probiotics, pulmonary inhalers, mucolytics, chronic infection management treatments, and diagnostic tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.